Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Hummingbird Bio Closes $125 Million Financing for Precision Medical Candidates

publication date: May 18, 2021

Singapore's Hummingbird Bioscience closed a $125 million Series C financing round led by Novo Holdings. The company is developing novel precision candidates by focusing on difficult-to-drug targets that have been biologically validated in cancer and autoimmune disease. Hummingbird has developed a platform based on a data-driven systems biology approach, which engineers next-gen therapies for unmet needs. It has announced three candidates, two of which have started clinical trials, one for HER3 cancers and another for advanced solid tumors. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital